Medartis Holding AG (SIX: MED) announced that its shareholders approved all substantive proposals of the Board of Directors with significant majorities at the Annual General Meeting (AGM) held on April 23, 2026, in Basel, Switzerland. The strong shareholder turnout, with 77.4% of total share capital represented, underscores investor confidence in the medical device company's leadership and strategic direction.
All seven members of the Board of Directors standing for re-election received resounding endorsement, each securing more than 93.8% support from represented votes. Yang Xu was newly elected to the Board of Directors with 99.7% endorsement and will join the Finance and Audit Committee, bringing fresh expertise to the board.
The AGM, held at Medartis headquarters in Basel, continued the tradition of direct shareholder engagement. Shareholders granted discharge to the Board members for their governance during the 2025 term and approved the proposed maximum total remuneration for both the Board of Directors and the Executive Management Board, including fixed and variable components. The 2025 management report and annual financial statements received nearly unanimous approval (99.99%), while the remuneration report was approved by 91.0% in a consultative vote. Additionally, the sustainability report gained strong endorsement (99.2%) of represented shares, confirming Medartis' commitment to transparent ESG practices.
Chairman Marco Gadola will continue to lead the Board. After two years with Medartis, Jennifer Dean decided not to stand for re-election. The assembly also confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee (HRCC), ensuring continuity in the oversight of the company's human capital strategy.
The newly constituted Board of Directors includes Marco Gadola (Chairman), Dr. h.c. Thomas Straumann (Vice Chairman), Willi Miesch, Damien Tappy, Nadia Tarolli Schmidt, Ciro Roemer, Martha Shadan, and Yang Xu. Committee assignments were confirmed with Marco Gadola and Damien Tappy on HRCC, and Yang Xu joining the Finance and Audit Committee alongside Nadia Tarolli Schmidt and Martha Shadan.
Shareholders also confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors, in accordance with the board's proposal.
Medartis also provided upcoming dates for its investor and corporate calendar. On June 4, 2026, Medartis will host an investor event in Basel, held on the fringes of the FESSH Hand Surgery Congress. The event is open to institutional investors and will provide an opportunity to engage with the company's management. The first-half 2026 results will be published on August 18, 2026, followed by the customary analyst and media briefing. The next Annual General Meeting is scheduled for April 22, 2027, at the company's headquarters in Basel.
The strong shareholder support and the election of Yang Xu reflect Medartis' focus on robust governance and strategic growth. For a detailed listing of all resolutions at the 2026 Annual General Meeting, please visit this link. More information about Medartis can be found at www.medartis.com.
